These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
370 related articles for article (PubMed ID: 7538734)
21. E-cadherin expression in prostate cancer: a broad survey using high-density tissue microarray technology. Rubin MA; Mucci NR; Figurski J; Fecko A; Pienta KJ; Day ML Hum Pathol; 2001 Jul; 32(7):690-7. PubMed ID: 11486167 [TBL] [Abstract][Full Text] [Related]
22. Computerized whole slide quantification shows increased microvascular density in pT2 prostate cancer as compared to normal prostate tissue. van Niekerk CG; van der Laak JA; Börger ME; Huisman HJ; Witjes JA; Barentsz JO; Hulsbergen-van de Kaa CA Prostate; 2009 Jan; 69(1):62-9. PubMed ID: 18780292 [TBL] [Abstract][Full Text] [Related]
23. A novel biomarker for staging human prostate adenocarcinoma: overexpression of matriptase with concomitant loss of its inhibitor, hepatocyte growth factor activator inhibitor-1. Saleem M; Adhami VM; Zhong W; Longley BJ; Lin CY; Dickson RB; Reagan-Shaw S; Jarrard DF; Mukhtar H Cancer Epidemiol Biomarkers Prev; 2006 Feb; 15(2):217-27. PubMed ID: 16492908 [TBL] [Abstract][Full Text] [Related]
24. Cathepsin B expression in prostate cancer of native Japanese and Japanese-American patients: an immunohistochemical study. Sinha AA; Morgan JL; Betre K; Wilson MJ; Le C; Marks LS Anticancer Res; 2008; 28(4B):2271-7. PubMed ID: 18751406 [TBL] [Abstract][Full Text] [Related]
25. Expression of vascular endothelial growth factor (VEGF) and association with microvessel density in benign prostatic hyperplasia and prostate cancer. Stefanou D; Batistatou A; Kamina S; Arkoumani E; Papachristou DJ; Agnantis NJ In Vivo; 2004; 18(2):155-60. PubMed ID: 15113042 [TBL] [Abstract][Full Text] [Related]
26. Promotion of angiogenesis by ps20 in the differential reactive stroma prostate cancer xenograft model. McAlhany SJ; Ressler SJ; Larsen M; Tuxhorn JA; Yang F; Dang TD; Rowley DR Cancer Res; 2003 Sep; 63(18):5859-65. PubMed ID: 14522910 [TBL] [Abstract][Full Text] [Related]
27. Elements regulating angiogenesis and correlative microvessel density in benign hyperplastic and malignant prostate tissue. Shih SJ; Dall'Era MA; Westphal JR; Yang J; Sweep CG; Gandour-Edwards R; Evans CP Prostate Cancer Prostatic Dis; 2003; 6(2):131-7. PubMed ID: 12806371 [TBL] [Abstract][Full Text] [Related]
28. Focal degeneration of basal cells and the resultant auto-immunoreactions: a novel mechanism for prostate tumor progression and invasion. Man YG; Gardner WA Med Hypotheses; 2008; 70(2):387-408. PubMed ID: 17658698 [TBL] [Abstract][Full Text] [Related]
29. Epigenetic events, remodelling enzymes and their relationship to chromatin organization in prostatic intraepithelial neoplasia and prostatic adenocarcinoma. Mohamed MA; Greif PA; Diamond J; Sharaf O; Maxwell P; Montironi R; Young RA; Hamilton PW BJU Int; 2007 Apr; 99(4):908-15. PubMed ID: 17378849 [TBL] [Abstract][Full Text] [Related]
31. Endothelial cell proliferation in prostatic carcinoma and prostatic hyperplasia: correlation with Gleason's score, microvessel density, and epithelial cell proliferation. Vartanian RK; Weidner N Lab Invest; 1995 Dec; 73(6):844-50. PubMed ID: 8558846 [TBL] [Abstract][Full Text] [Related]
32. Immunohistochemical expression of retinoblastoma and p53 tumor suppressor genes in prostatic intraepithelial neoplasia: comparison with prostatic adenocarcinoma and benign prostate. Tamboli P; Amin MB; Xu HJ; Linden MD Mod Pathol; 1998 Mar; 11(3):247-52. PubMed ID: 9521470 [TBL] [Abstract][Full Text] [Related]
33. Reduction of human prostate tumor vascularity by the alpha1-adrenoceptor antagonist terazosin. Keledjian K; Borkowski A; Kim G; Isaacs JT; Jacobs SC; Kyprianou N Prostate; 2001 Jul; 48(2):71-8. PubMed ID: 11433417 [TBL] [Abstract][Full Text] [Related]
34. Salient and co-morbid features in benign prostatic hyperplasia: a histopathological study of the prostate. Shakya G; Malla S; Shakya KN Kathmandu Univ Med J (KUMJ); 2003; 1(2):104-9. PubMed ID: 16388207 [TBL] [Abstract][Full Text] [Related]
35. High-grade foamy gland prostatic adenocarcinoma on biopsy or transurethral resection: a morphologic study of 55 cases. Zhao J; Epstein JI Am J Surg Pathol; 2009 Apr; 33(4):583-90. PubMed ID: 19033862 [TBL] [Abstract][Full Text] [Related]
36. Expression analysis of peptide growth factors VEGF, FGF2, TGFB1, EGF and IGF1 in prostate cancer and benign prostatic hyperplasia. Soulitzis N; Karyotis I; Delakas D; Spandidos DA Int J Oncol; 2006 Aug; 29(2):305-14. PubMed ID: 16820871 [TBL] [Abstract][Full Text] [Related]
37. Vascular endothelial growth factor (VEGF) expression in prostate cancer and benign prostatic hyperplasia. Jackson MW; Bentel JM; Tilley WD J Urol; 1997 Jun; 157(6):2323-8. PubMed ID: 9146664 [TBL] [Abstract][Full Text] [Related]
38. IL-6, IL-10 and HSP-90 expression in tissue microarrays from human prostate cancer assessed by computer-assisted image analysis. Cardillo MR; Ippoliti F Anticancer Res; 2006; 26(5A):3409-16. PubMed ID: 17094460 [TBL] [Abstract][Full Text] [Related]
39. Immunohistochemical comparative analysis of transforming growth factor alpha, epidermal growth factor, and epidermal growth factor receptor in normal, hyperplastic and neoplastic human prostates. De Miguel P; Royuela ; Bethencourt R; Ruiz A; Fraile B; Paniagua R Cytokine; 1999 Sep; 11(9):722-7. PubMed ID: 10479409 [TBL] [Abstract][Full Text] [Related]
40. Expression of different vascular endothelial markers in prostate cancer and BPH tissue: an immunohistochemical and clinical evaluation. Trojan L; Thomas D; Friedrich D; Grobholz R; Knoll T; Alken P; Michel MS Anticancer Res; 2004; 24(3a):1651-6. PubMed ID: 15274336 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]